What it's for (Indications)
- Cefdinir is a broad-spectrum, semi-synthetic, third-generation cephalosporin antibiotic indicated for the treatment of mild to moderate infections caused by susceptible strains of microorganisms.
- Its primary indications include community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute bacterial otitis media, and uncomplicated skin and skin structure infections.
- It is effective against a range of Gram-positive and Gram-negative bacteria, including *Streptococcus pneumoniae* (penicillin-susceptible strains only), *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus aureus* (methicillin-susceptible strains).
- The choice of cefdinir should be guided by local epidemiological patterns of susceptibility and resistance, or by microbiological confirmation of the causative pathogen's susceptibility.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefdinir varies based on the age of the patient, the type and severity of the infection, and renal function. For adults and adolescents (13 years and older), the typical dosage is 300 mg orally every 12 hours or 600 mg orally once daily for 5 to 10 days, depending on the infection. For pediatric patients (6 months to 12 years of age), the recommended dosage is 14 mg/kg/day, administered either as 7 mg/kg every 12 hours or 14 mg/kg once daily, with a maximum daily dose of 600 mg. Dosage adjustments are crucial for patients with significantly impaired renal function (creatinine clearance less than 30 mL/min), where a dose of 300 mg once daily is typically recommended. It is important to complete the full course of therapy as prescribed, even if symptoms improve, to prevent the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Cefdinir, like other antibiotics, can cause a range of side effects, most of which are mild and transient.
- The most commonly reported adverse reactions include gastrointestinal disturbances such as diarrhea, nausea, abdominal pain, and vomiting.
- Other common side effects may include headache and vaginal moniliasis.
- More serious, albeit less frequent, side effects can occur, including severe cutaneous adverse reactions (e.
- g.
- , Stevens-Johnson syndrome, toxic epidermal necrolysis), *Clostridioides difficile*-associated diarrhea (CDAD), and allergic reactions ranging from rash and pruritus to severe anaphylaxis.
- Hematologic abnormalities (e.
- g.
- , eosinophilia, leukopenia, thrombocytopenia) and changes in liver enzyme levels have also been reported.
- Patients should be advised to seek immediate medical attention if they experience severe diarrhea, rash, difficulty breathing, or swelling of the face or throat.
Serious Warnings
- Black Box Warning: While cefdinir (Dinacor) does not carry a specific FDA Black Box Warning, healthcare professionals and patients must be aware of several critical safety considerations. Severe and potentially fatal hypersensitivity reactions, including anaphylaxis, have been reported with beta-lactam antibiotics, including cephalosporins. Patients with a history of penicillin allergy, particularly immediate severe reactions, should be closely monitored, as cross-reactivity can occur. Furthermore, treatment with antibacterial agents, including cefdinir, alters the normal flora of the colon and may permit overgrowth of *Clostridioides difficile*. This can lead to *Clostridioides difficile*-associated diarrhea (CDAD), which ranges in severity from mild diarrhea to fatal colitis. CDAD can occur more than two months after antibiotic administration, necessitating careful patient evaluation. Renal impairment necessitates dosage adjustment to prevent accumulation and potential toxicity. Patients should also be advised regarding potential interactions with iron-containing products and antacids, which can significantly reduce cefdinir absorption if not properly spaced. Additionally, prolonged use may result in the overgrowth of non-susceptible organisms, highlighting the importance of appropriate antimicrobial stewardship and reassessment of therapy if superinfection occurs. These serious warnings underscore the importance of judicious prescription and patient monitoring.
- Several critical warnings are associated with cefdinir therapy.
- Hypersensitivity reactions, including severe and occasionally fatal anaphylactic reactions, have been observed in patients receiving beta-lactam antibiotics.
- Careful inquiry about previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs is essential before initiating therapy.
- If an allergic reaction occurs, cefdinir should be discontinued immediately.
- *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including cefdinir, and can range in severity from mild diarrhea to fatal colitis; it is crucial to consider this diagnosis in patients presenting with diarrhea after antibiotic use.
- Dosage adjustments are necessary for patients with renal impairment to prevent accumulation.
- Furthermore, co-administration with iron-containing products or antacids can significantly reduce cefdinir absorption, necessitating spaced administration.
- Prolonged use may lead to overgrowth of non-susceptible organisms, requiring re-evaluation of treatment.
How it Works (Mechanism of Action)
Cefdinir exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. As a third-generation cephalosporin, it achieves this by covalently binding to and inactivating penicillin-binding proteins (PBPs) located within the bacterial cell membrane. PBPs are crucial enzymes involved in the transpeptidation process, which is responsible for the cross-linking of peptidoglycan units, a vital component for the structural integrity and rigidity of the bacterial cell wall. By disrupting this critical step, cefdinir leads to a weakened cell wall, increased osmotic pressure, and ultimately, lysis and death of the bacterial cell. Cefdinir demonstrates good stability in the presence of many bacterial beta-lactamases, which contributes to its broad spectrum of activity against various Gram-positive and Gram-negative pathogens.